

NEWSLETTER MULTIPLEMS

#4 | FEBRUARY 2019



MultipleMS

Contact information:

- Official webpage: <http://www.multiplems.eu>
- Stakeholder registration: <http://www.multiplems.eu/Newsletters/>
- Facebook: www.facebook.com/multipleMS
- Twitter: @MultipleMS_EU



Prospective study

We have recruited more than **200 patients** in this prospective study. We aim for **300 patients** at the end of March, and in total 500 patients will be included. The first patients that were recruited last year have already been re-sampled at the 6 and 12-month visit.


Retrospective study

The the first phase of the genetic analysis is completed, meaning that all genetic data is comparable between individual contributing centres. All centres will receive their data in this comparable format for local analyses.



MultipleMS members

In this issue we present the team members from TUM (Technical University of Munich) School of Medicine, Germany, who are part of the MultipleMS work package 5, called “Biomarkers and Therapeutic Targets”. Their responsibilities include among others: developing a pipeline for identification of new MS biomarkers and new therapeutic strategies. They are also in charge of the prospective study, namely coordinating and handling all the biomaterial samples collected from newly diagnosed patients across the different centres.



The TUM team. From left: Carina Nowak, Ana Klein, Verena Grummel, Dorothee Kohberger

“At our site, we are responsible for the initial preparation of pre-labeled sampling and processing kits and shipping these to the centers. After collection and preparation of samples the centers return the kits to our site, where they are aliquoted and stored at -80°C .

In addition to this, like every center, we are responsible for patient recruitment, data acquisition and preparation of all in-house samples”

- **Ana Klein**